Compare SIMO & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SIMO | BMRN |
|---|---|---|
| Founded | 1995 | 1996 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.4B | 10.4B |
| IPO Year | 2005 | 1999 |
| Metric | SIMO | BMRN |
|---|---|---|
| Price | $300.71 | $58.97 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 18 |
| Target Price | ★ $118.13 | $88.22 |
| AVG Volume (30 Days) | 877.8K | ★ 1.9M |
| Earning Date | 04-28-2026 | 05-04-2026 |
| Dividend Yield | ★ 0.92% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.54 |
| Revenue | N/A | ★ $1,313,646,000.00 |
| Revenue This Year | $42.27 | $15.02 |
| Revenue Next Year | $12.78 | $12.23 |
| P/E Ratio | ★ $36.09 | $109.20 |
| Revenue Growth | N/A | ★ 17.62 |
| 52 Week Low | $70.12 | $49.26 |
| 52 Week High | $355.00 | $66.28 |
| Indicator | SIMO | BMRN |
|---|---|---|
| Relative Strength Index (RSI) | 52.32 | 61.76 |
| Support Level | $91.95 | $53.32 |
| Resistance Level | $314.34 | $61.92 |
| Average True Range (ATR) | 24.43 | 1.49 |
| MACD | -2.00 | 0.19 |
| Stochastic Oscillator | 42.85 | 85.48 |
Silicon Motion Technology Corp is engaged in developing NAND flash controllers for SSDs and other solid-state storage devices. Its only operating segment is to develop NAND flash controllers and SSD solutions. The company derives revenue from product categories such as Mobile Storage, Mobile Communications, and others. Silicon's geographical segments are Taiwan, the United States, Korea, China, Singapore, Malaysia, and others. The company's products are used in Personal Computing, Smartphone/Tablet/CE, Flash Card/USB Flash Drive, Industrial and Embedded, Automotive, and Enterprise and Data centers.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.